Psychedelics
Awakn Life Sciences starts study on ketamine treatment for gambling addiction
Toronto-based biotechnology company Awakn has a research program on ketamine-assisted psychotherapy against multiple addictions.
Study examines challenges in integrating psilocybin therapy with palliative care
Coryn Mayer says the healthcare system needs to improve if psilocybin therapy is to become a mainstream tool.
Vancouver’s Havn Life announces first psilocybin mushroom harvest in Jamaica
Vancouver biotechnology company Havn Life will export yield to UBC-based Delic Labs for quality control and testing.
Numinus subsidiary files U.S. patent application for rapid production of psychedelic treatments
The Vancouver-based company has a licence from Health Canada to test, sell, and distribute psychedelic substances.
Psychedelics researcher explains why a bad trip is a good one after all
Petter Grahl Johnstad of the University of Bergen says a bad psychedelics trip can be a way to confront personal demons.
Cybin Inc. announces revolutionary study of ketamine with neuroimaging helmet
Toronto-based Cybin plans to look at real time effects of ketamine on the brain.